[Effects of krestin (PSK) on drug-metabolizing enzymes with special reference to the activation of FT-207].
The effects of PSK on hepatic drug-metabolizing enzymes were investigated using Sarcoma 180-bearing and non-tumor-bearing ICR mice. PSK, an immunomodulator, has been commonly used in combination with tegafur for post-operative adjuvant chemotherapy. Tegafur is a typical masked compound transformed into 5-FU by the hepatic drug-metabolizing enzyme P-450. It has been reported that immunostimulants such as BCG and anaerobic Corynebacterium suppress the drug metabolism. PSK and Propionibacterium acnes were administered to mice inoculated s.c. with Sarcoma 180. It was demonstrated that Propionibacterium acnes had an effect of inhibiting these enzymatic activities, especially the amount of P-450 and cytochrome b5 and aminopyrine demethylation. On the other hand, PSK had no influence on the drug-metabolizing enzymes. Propionibacterium acnes was shown to decrease the 5-FU level in organs and sera of mice given FT-207 orally. By contrast, PSK showed no difference in 5-FU level compared to controls, indicating that PSK had no inhibitory effect on the activation of FT-207 by hepatic drug-metabolizing enzymes.
D000632:Aminopyrine / Q000378:metabolism; D000818:Animals; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D003573:Cytochrome b Group / Q000378:metabolism; D015786:Cytochromes b5; D005472:Fluorouracil / Q000032:analysis; D051379:Mice; D008813:Mice, Inbred ICR; D008862:Microsomes, Liver / Q000201:enzymology; D011425:Propionibacterium acnes; D011509:Proteoglycans / Q000494:pharmacology*; D012510:Sarcoma 180 / Q000201:enzymology*; D005641:Tegafur / Q000378:metabolism*
D003573:Cytochrome b Group; D011509:Proteoglycans; D000632:Aminopyrine; D005641:Tegafur; C010770:polysaccharide-K; D015786:Cytochromes b5; D003577:Cytochrome P-450 Enzyme System; D005472:Fluorouracil